A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

This Phase III trial compares a new drug called HRS-4357 to existing hormone-blocking treatments for advanced prostate cancer that has become resistant to castration (hormone therapy) and has spread to other parts of the body. The cancer must also show a protein called PSMA on its cells. **You may be eligible if...** - You are a male aged 18 or older - You have confirmed metastatic castration-resistant prostate cancer (mCRPC) — prostate cancer that has spread and is no longer responding to hormone therapy - Your cancer tests positive for PSMA (a protein on prostate cancer cells) - Your disease is progressing - Your general health is good (ECOG 0–1) and life expectancy is at least 6 months **You may NOT be eligible if...** - Your cancer does not have PSMA - Your prostate cancer has not yet become castration-resistant - You have major organ problems or other conditions preventing participation Talk to your doctor to see if this trial is right for you.